Cardio Diagnostics Holdings, Inc. (CDIO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.67

From 52W high−74.96%

Volume12514.00

Market cap$4.85M

P/E (TTM)—

P/S (TTM)335.9x

Div yield—

Key dataOct 19, 2026

Open

$1.67

From 52W high

−74.96%

Volume

12514.00

Market cap

$4.85M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

P/E (TTM)

—

RSI (14)

35.6

MomentumView details →

1D Return

−2.96%

YTD Return

−39.11%

SummaryUpdated Jun 1, 2026

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) is a biotechnology company founded in 2017 and headquartered in Chicago, Illinois. The company went public in January 2022 and specializes in developing and commercializing advanced diagnostic tests for cardiovascular disease using epigenetic technology. As a relatively young public company in the precision medicine space, Cardio Diagnostics focuses on creating innovative testing solutions that can help predict and assess cardiovascular risk before symptoms appear.

Ask drillr about Cardio Diagnostics Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.1x

EV/Sales

−25.2x

P/S (TTM)

335.9x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

−555.03%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−87.12%

ROA (TTM)

−81.62%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−25.92%

EPS YoY

+21.76%

FCF YoY

−4.05%

Revenue CAGR 3Y

+149.89%

EPS CAGR 3Y

+60.11%

EBITDA YoY

−3.95%

MomentumView details →

1D Return

−2.96%

YTD Return

−39.11%

1Y Return

−63.25%

RSI (14)

35.6

vs 50D SMA

−14.06%

vs 200D SMA

−21.40%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

17.15x

Quick Ratio

17.15x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.51

EPS Surprise

—

Beats (12Q)

7/12

Next Q EPS Est

−$19.80

Avg Surprise (4Q)

55.28%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

14450.00

Net Income (TTM)

−6.47M

Op. CF (TTM)

−5.66M

Next earningsNov 6, 2026 →

Latest newsMore news →

Atlas Healthcare Physicians agreed to cover Cardio Diagnostics' precision cardiovascular medicine tests for its members starting May 2026.117d ago

Similar companies

Processa Pharmaceuticals, Inc.PCSA Galmed Pharmaceuticals Ltd.GLMD XTL Biopharmaceuticals Ltd.XTLB Medicus Pharma Ltd. Common StockMDCX NeuroSense Therapeutics Ltd.NRSN Addex Therapeutics LtdADXN Find similar companies →

Latest newsMore news →

Atlas Healthcare Physicians agreed to cover Cardio Diagnostics' precision cardiovascular medicine tests for its members starting May 2026.117d ago